Print

Autumn 2012 E-Newsletter

Autumn 2012 UCLA Alzheimer's Research Center Newsletter

| Phase III AD Trial Results | 2012 Spanish Thank You Luncheon | Dear Doc... |
| Support Group | Clinical Trials | Upcoming Event |

Phase III Alzheimer's Disease Clinical Trial Results Announced
By: Joshua Grill, Ph.D.

Phase III Alzheimer's Disease Clinical Trial Results Announced Late this summer, the initial results of a series of large Phase III clinical trials of investigational agents in development for Alzheimer's disease (AD) were announced. Four studies of two investigational drugs concluded their initial analyses and found no benefit of either drug. The two drugs, bapineuzumab and solanezumab, are both antibodies against the protein that builds up in the brains of persons with AD. The hope in these studies was that treatment would slow accumulation or reduce the total amount of the protein in the brain, and that this would slow progression of the decline that occurs in AD.

Unfortunately, for each of the four studies, this did not turn out to be case. None of the studies found that the treatment could slow cognitive or functional decline in patients who received the treatment, relative to persons who were randomly assigned to get a placebo (inactive drug).

Though Alzheimer's researchers, advocates, patients, and families were hoping for success in these studies, what is most important is that researchers learn from them. And we will.

These trials provide substantial and potentially pivotal information in the fight against AD. They enrolled thousands of participants and collected a wide array of biomarkers (biological measures of what happens in the brain and bodily fluids of persons with AD). These data will provide invaluable information and represent a step toward our ultimate goal of improved therapies for people with Alzheimer’s disease.

Importantly, this step could not have been taken without the thousands of Alzheimer's patients and family members who participated. The Easton Center's faculty and staff send our heartfelt appreciation to the participants in these studies who enrolled at UCLA and nation- and world-wide. Clinical trials that take the next steps toward improved treatments are ongoing and always need more participants.

top

2012 Spanish Thank You Luncheon

2012 Spanish Thank You Luncheon

On Saturday, August 25th, the Easton Center said, "Gracias" to our Spanish-speaking research participants. A luncheon was held at the Olive View Medical Center, where the Easton Center enrolls research participants from the San Fernando Valley. This site features a research team including Drs. Shelly Wolf and Freddy Ortiz, and Norma Guerra (research coordinator). Each year, this luncheon is held in appreciation of those who participate in the Center's Longitudinal study. The luncheon was well attended by research participants and their families. The Alzheimer's Association, and other community resources had information tables at the event, providing attendees with resources and literature about Alzheimer's disease. The next Spanish Thank You luncheon will be held in Summer 2013.

top


Dear Doc...

I recently learned that the FDA has approved a bigger Exelon patch. Should I ask my doctor to prescribe this for my mom, who is currently on the previously recommended dosage?
Thanks,
Herman

Thank you for sending your question. The new larger patch was approved because its safety and efficacy was demonstrated in a clinical trial. Prior to the OPTIMA (Optimizing Transdermal Exelon in Mild-to-moderate Alzheimer's disease) study, the Exelon patch®(also known as rivastigmine) was approved by the Federal Drug Administration (FDA) at dosages of either 4.6 or 9.5 mg per 24 hours. The new maximum dosage that is FDA approved for treatment of mild to moderate Alzheimer's disease (AD) is 13.3 mg over 24 hours.

OPTIMA was a 72- to 96-week clinical trial in which 1584 mild to moderate Alzheimer's patients were given the original FDA approved dosage of 9.5 mg/24 h for 24- to 48-weeks. Those who were able to tolerate the 9.5 mg/24 h dosage were then randomized into a 1:1 double blind phase (neither the participant nor the research staff knew whether participant was receiving the new, higher dose or were kept at the standard dose). This phase lasted 48 weeks. To be selected for the double blind phase of the study, participants had to show cognitive and functional decline during the first phase of the study. In total 567 people showed decline; 280 were assigned to the 13.3 mg/24 h group and 287 remained at the 9.5 mg/24 h dosage. The higher dose did not show an increase in side effects, except slightly more participants in the 13.3 mg/24 h dose experienced a decrease in weight. Researchers found that, while both groups showed functional and cognitive decline, the group that received the higher dosage declined less (Cummings et al, 2012). For more detailed information about this study, please click here.

Exelon is a cholinesterase inhibitor. Medications in this category prevent the breakdown of acetylcholine, which is a brain chemical important in learning and memory. Other medicines in this class include donepezil (Aricept®) and galantamine (Razadyne®). Exelon is the only AD medication that is available in patch form.

The higher dose of Exelon has been FDA approved. Before switching to the higher dose, patients and their families should discuss it at length with the physician who treats their memory problems. Other considerations, such as tolerability and effectiveness of the current dose, are important before making changes.

Sincerely,

Dear Doctors
Sarah Kremen, M.D.
Physician

Please send us your questions via email to
This email address is being protected from spambots. You need JavaScript enabled to view it. .
We look forward to hearing from you!

top


Support Group at the Easton Center

Caring for a loved one with dementia can be difficult and stressful. The Easton Center, in collaboration with the Alzheimer's Association, holds a support group for caregivers of patients with dementia. The group convenes the first and third Wednesday of each month from 1 pm – 2:30 pm at the Easton Center (10911 Weyburn Ave, 2nd Floor, Los Angeles, CA 90095). If you, or someone you know would like to join this group, please call (310) 794-6039 for more information.

top

Clinical Research Opportunities

If you would like to advance Alzheimer's disease research, please consider participating at the Easton Center. Below are two current trials. For a complete list of enrolling studies, visit our website at www.eastonad.ucla.edu.

Alzheimer's Disease NeuroImaging Initiative (ADNI):

This large multi-site project aims to define the rate of progression of mild cognitive impairment and Alzheimer's disease and to develop improved methodologies including biomarkers for AD clinical trials. It is a non-randomized natural history non-treatment study, which enrolls cognitively normal subjects as well as those with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD). Enrolled subjects should be between 55-90 years of age, have a study partner able to provide an independent evaluation of functioning, and will speak either English or Spanish fluently. All subjects must be willing and able to undergo all test procedures including detailed cognitive testing, neuroimaging, lumbar punctures and blood draws. For more information, please call(310) 794-6039 or www.eastonad.ucla.edu.

Study of Brain Metabolic Effects of Axona®:

This study will use positron emission tomography (PET) scans to examine the effects of the medical food Axona® on blood flow to the brain in patients with Alzheimer's disease (AD). The study involves 3 visits to the clinic over the course of 45 days. 90% of participants in this study will receive the active medical food product and 10% of participants will receive a placebo (inactive product). Participants will be examined by a doctor as well as partake in cognitive testing, blood draws, and PET scans. Potential side effects of participating in this study are generally mild and will be carefully monitored throughout the study. To be eligible for this study, one must be diagnosed with Alzheimer's disease, between 50 and 90 years old, and in good health. For more information, please contact the UCLA Mary S. Easton Center for Alzheimer's Disease Research at (310) 794-6039 or www.eastonad.ucla.edu.

top

Upcoming Event

2012 Walk to End Alzheimer's™ in Century City, CA

Date: Sunday, November 4th, 2012
Time: 7:00 a.m. - 12:00 p.m.
Location: Century Park, Century City, CA

Join the Alzheimer's Association Walk to End Alzheimer's™ and unite in a movement to reclaim the future for millions. With more than 5 million Americans living with Alzheimer's, and nearly 11 million more serving as caregivers, the time to act is now! CLICK HERE to join the Easton Center team.


Our mailing address is:
Mary S. Easton Center for Alzheimer's Disease Research at UCLA
10911 Weyburn Avenue, Suite #200
Los Angeles, CA 90095-7226
http://www.eastonad.ucla.edu | Phone Number: (310) 794-6039
forward to a friend | This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it.
Copyright © 2012. Mary S. Easton Center for Alzheimer's Disease Research at UCLA. All rights reserved.

top